Clozapine, but not haloperidol, prevents the functional hyperactivity of N-methyl-D-aspartate receptors in rat cortical neurons induced by subchronic administration of phencyclidine

Journal of Pharmacology and Experimental Therapeutics

Volumn 289, Issue 2, 1999, Pages 1000-1006

  Arvanov, V L ^a   Wang, Rex Y ^a  

^a STONY BROOK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; CLOZAPINE; HALOPERIDOL; LIDOCAINE ETHOBROMIDE; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROLEPTIC AGENT; PHENCYCLIDINE; TETRODOTOXIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; BRAIN SLICE; COGNITIVE DEFECT; CONFERENCE PAPER; CONTROLLED STUDY; DRUG MECHANISM; EXCITATORY POSTSYNAPTIC POTENTIAL; MALE; NEGATIVE SYNDROME; NEUROTRANSMISSION; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT; SCHIZOPHRENIA; VOLTAGE CLAMP;

ALPHA-AMINO-3-HYDROXY-5-METHYL-4-ISOXAZOLEPROPIONIC ACID; ANIMALS; ANTIPSYCHOTIC AGENTS; CLOZAPINE; EXCITATORY AMINO ACID AGONISTS; EXCITATORY AMINO ACID ANTAGONISTS; EXCITATORY POSTSYNAPTIC POTENTIALS; HALOPERIDOL; MALE; MEMBRANE POTENTIALS; N-METHYLASPARTATE; NEURONS; PATCH-CLAMP TECHNIQUES; PHENCYCLIDINE; PREFRONTAL CORTEX; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, N-METHYL-D-ASPARTATE; SYNAPTIC TRANSMISSION;

EID: 0032955974     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (64)

1. Alessandri B, Battig K and Welzl H (1989) Effects of ketamine on tunnel maze and water maze performance in the rat. Behav Neural Biol 52:194-212.
2. Arvanov VL, Liang X, Schwartz J, Grossman S and Wang RY (1997) Clozapine and haloperidol modulate NMDA- and non-NMDA-receptor mediated transmission in rat prefrontal cortical neurons in vitro. J Pharmacol Exp Ther 283:226-234.
3. Arvanov VL and Wang RY (1997) NMDA-evoked response in pyramidal neurons of the rat medial prefrontal cortex slices consists of NMDA and non-NMDA components. Brain Res 768:361-364.
4. 2A receptor antagonist and a potential antipsychotic drug, facilitates NMDA-receptor mediated neurotransmission in the rat medial prefrontal cortical neurons in vitro. Neuropsychopharmacology 18:197-209.
5. Beart PM and Lodge D (1990) Chronic administration of MK-801 and the NMDA receptor: Further evidence for reduced sensitivity of the primary acceptor site from studies with the cortical wedge preparation. J Pharm Pharmacol 42:354-355.
6. Berretta N and Jones RSG (1996) Tonic facilitation of glutamate release by presynaptic N-methyl-D-aspartate autoreceptors in the entorhinal cortex. Neuroscience 76:339-344.
7. Boyce S, Rupniak NM, Steventon MJ, Cook G and Iversen SD (1991) Psychomotor activity and cognitive disruption attributable to NMDA, but not sigma, interactions in primates. Behav Brain Res 42:115-121.
8. Carlsson M and Carlsson A (1990) Interactions between glutamatergic and monoaminergic systems within the basal ganglia - implications for schizophrenia and Parkinson's disease. Trends Pharmacol Sci 13:272-276.
9. Chen X, Michaelis ML and Michaelis EK (1997) Effects of chronic ethanol treatment on the expression of calcium transport carriers and NMDA/glutamate receptor proteins in brain synaptic membranes. J Neurochem 69:1559-1569.
10. Connick JH and Stone TW (1988) Quinolinic acid effects on amino acid release from the rat cerebral cortex in vitro and in vivo. Br J Pharmacol 93:868-876.
11. Cosgrove J and Newell TG (1991) Recovery of neuropsychological functions during reduction in use of phencyclidine. J Clin Psychol 47:159-169.
12. Danysz W, Wroblewski JT and Costa E (1988) Learning impairment in rats by N-methyl-D-aspartate receptor antagonists. Neuropharmacology 27:653-656.
13. Deutsch SI, Mastrpaolo J, Schwartz BL, Rosse RB and Morihisa JM (1989) A "glutamatergic hypothesis" of schizophrenia: rationale for pharmacology with glycine. Clin Neuropharmacol 12:1-13.
14. Finkel AS and Redman SJ (1985) Optimal voltage clamping with single microelectrodes, in Voltage and Patch Clamping with Microelectrodes (Smith TG, Lecar A, Redman SJ, Gage PW eds) pp 95-120, Williams & Wilkins, Baltimore.
15. Freund G and Anderson KJ (1996) Glutamate receptors in the frontal cortex of alcoholics. Alcoholism 20:1165-1172.
16. 3H]kainate binding in hippocampus 24 hours after PCP. Neurosci Lett 174: 149-153.
17. Gao XM and Tamminga CA (1995) MK801 induces late regional increases in NMDA and kainate receptor binding in rat brain. J Neural Transm 101:105-113.
18. 3H]MK801-binding sites in the rat brain: a side-preference action in cortical areas. Brain Res 762:216-218.
19. Goldman Rakic PS and Selemon LD (1997) Functional and anatomical aspects of prefrontal pathology in schizophrenia. Schizophr Bull 23:437-458.
20. Hess G, Kuhnt U and Voronin LL (1987) Quantal analysis of paired-pulse facilitation in guinea pig hippocampal slices. Neurosci Lett 77:187-192.
21. Holmes K, Keele B, Arvanov V and Shinnick-Gallagher P (1996) Metabotropic glutamate receptor agonist-induced hyperpolarization in rat basolateral amygdala neurons: Receptor characterization, second messengers and ion channels. J Neurophysiol 76:3059-3069.
22. Honey CR, Miljkovic Z and McDonald JF (1985) Ketamine and phencyclidine cause a voltage-dependent block of responses to L-aspartic acid. Neurosci Lett 61:135-139.
23. Huettner JE and Bean BP (1988) Blok of N-methyl-D-aspartate-activated current by the anticonvulsant MK-801: Selective binding to open channels. Proc Natl Acad Sci USA 85:1307-1311.
24. Javitt DC and Zukin SR (1991) Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatr 148:1301-1308.
25. Jentsch JD, Redmond DE Jr, Elsworth JD, Taylor JR, Youngren KD and Roth RH (1997a) Enduring cognitive deficits and cortical dopamine dysfunction in monkeys after long-term administration of phencyclidine. Science (Wash DC) 277:953-955.
26. Jentsch JD, Tran A, Le D, Youngren K and Roth RH (1997b) Subchronic phencyclidine administration reduces mesoprefrontal dopamine utilization and impairs prefrontal cortical-dependent cognition in the rat. Neuropsychopharmacology 17: 92-99.
27. 2A antagonist with a favorable CNS safety profile. J Pharmacol Exp Ther 277:968-981.
28. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, Heninger GR, Bowers MB Jr and Charney DS (1994) Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 51:199-214.
29. Lahti AC, Koffel B, Laporte D and Tamminga CA (1995) Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology 13:9-19.
30. MacDonald JF, Miljkovic Z and Pennefather P (1987) Use-dependent block of excitatory amino acid currents in cultured neurons by ketamine. J Physiol (Lond) 58:251-266.
31. Madison DV, Lancaster B and Nicoll RA (1987) Voltage clamp analysis of cholinergic action in the hippocampus. J Neurosci 7:733-741.
32. Malhotra AK, Adler CM, Kennison SD, Elman I, Pickar D and Breier A (1997) Clozapine blunts N-methyl-D-aspartate antagonist-induced psychosis: A study with ketamine. Biol Psychiatry 42:664-668.
33. Malhotra AK, Finals DA, Weingartner H, Sirocco K, Missar CD, Pickar D and Breier A (1996) NMDA receptor function and human cognition: The effects of ketamine in healthy volunteers. Neuropsychopharmacology 14:301-307.
34. Malinow R and Tsien RW (1990) Presynaptic enhancement shown by whole-cell recordings of long-term potentiation in hippocampal slices. Nature (Lond) 346: 177-180.
35. 3H]D-AP5, suggesting down-regulation of the cortical N-methyl-D-aspartate receptors. Neuroscience 30:87-94.
36. McCoy L and Richfield EK (1996) Chronic antipsychotic treatment alters glycine-stimulated NMDA receptor binding in rat brain. Neurosci Lett 213:137-141.
37. McDonald JW, Silverstein FS and Johnston MV (1990) MK-801 pretreatment enhances N-methyl-D-aspartate-mediated brain injury and increases brain N-methyl-D-aspartate recognition site binding in rats. Neuroscience 38:103-113.
38. Misra AL, Pontani RB and Bartolomeo J (1979) Persistence of phencyclidine (PCP) and metabolites in brain and adipose tissue and implications for long-lasting behavioral effects. Res Commun Chem Pathol Pharmacol 24:431-445.
39. Montague PR, Gancayco CD, Winn MJ, Marchase RB and Friedlander MJ (1994) Role of NO production in NMDA receptor-mediated neurotransmitter release in cerebral cortex. Science (Wash DC) 263:973-977.
40. Oh S, Hoshi K and Ho IK (1997) Role of NMDA receptors in pentobarbital tolerance/ dependence. Neurochem Res 22:767-774.
41. Olney JW and Farber NB (1995) Glutamate receptor disfunction and schizophrenia. Arch Gen Psychiatry 52:998-1007.
42. Pearlson GD (1981) Psychiatric and medical syndromes associated with phencyclidine (PCP) abuse. Johns Hopkins Med J 148:25-33.
43. Quirion R, Bayorh MA, Zerbe RL and Pert CB (1982) Chronic phencyclidine treatment decreases phencyclidine and dopamine receptors in rat brain. Pharmacol Biochem Behav 17:699-702.
44. Rainnie DG, Holmes KH and Shinnick-Gallagher P (1994) Activation of postsynaptic metabotropic glutamate receptors by trans-ACPD hyperpolarizes neurons of the basolateral amygdala. J Neurosci 14:7208-7220.
45. Riva MA, Tascedda F, Lovati E and Racagni G (1997) Regulation of NMDA receptor subunit messenger RNA levels in the rat brain following acute and chronic exposure to antipsychotic drugs. Mol Brain Res 50:136-142.
46. Sams-Dodd F (1998) A test of the predictive validity of animal models of schizophrenia based on phencyclidine and d-amphetamine. Neuropsychopharmacology 18: 293-304.
47. Saransaari P, Lillrank SM and Oja SS (1993) Phencyclidine treatment in mice: effects on phencyclidine binding sites and glutamate uptake in cerebral cortex preparations. J Neural Transm Gen Sect 93:47-59.
48. Schmidt WJ (1994) Behavioural effects of NMDA-receptor antagonists. J Neural Transm (Suppl) 43:63-69.
49. Schweitzer P, Madamba S, Champagnat J and Siggins GR (1993) Somatostatin inhibition of hippocampal CA1 pyramidal neurons: mediation by arachidonic acid and its metabolites. J Neurosci 13:2033-2049.
50. Sturgeon RD, Fesslen R, London SF and Meltzer HY (1982) Behavioral effects of chronic phencyclidine administration in rats. Psychopharmacology 76:52-56.
51. Tanaka S, Kiuchi Y, Numazawa S, Oguchi K, Yoshida T and Kuroiwa Y (1997) Changes in glutamate receptors, c-fos mRNA expression and activator protein-1 (AP-1) DNA binding activity in the brain of phenobarbital-dependent and -withdrawn rats. Brain Res 756:35-45.
52. Terazi FI, Florijn WJ and Creese I (1996) Regulation of ionotropic glutamate receptors following subchronic and chronic treatment with typical and atypical antipsychotics. Psychopharmacology 128:371-379.
53. Verebey K, Kogan MJ and Mule SJ (1981) Phencyclidine-induced stereotypy in rats: Effects of methadone, apomorphine, and naloxone. Psychopharmacology 75:44-47.
54. Verma A and Moghaddam B (1996) NMDA receptor antagonists impair prefrontal cortex function as assessed via spatial delayed alternation performance in rats: modulation by dopamine. J Neurosci 16:373-379.
55. Wachtel H and Turski L (1990) Glutamate: A new target in schizophrenia. Trends Pharmacol Sci 11:219-220.
56. Wang RY and Liang XF (1998a) M100907 and clozapine, but not haloperidol or raclopride, prevent phencyclidine-induced blockade of NMDA responses in pyramidal neurons of the rat medial prefrontal cortical slice. Neuropsychopharmacology 19:74-85.
57. Wang RY and Liang X (1998b) Olanzapine: Facilitation of NMDA receptor-mediated neurotransmission and the induction of long-term potentiation in hippocampal CA1 region, 7th Neuropharmacology Conference, Abstract 93.
58. Wang RY, Arvanov VL and Liang X (1998) Modulation of NMDA- and AMPA-responses in pyramidal neurons of the rat medial prefrontal cortex by chronic treatment with haloperidol or clozapine. Neurosci Abstr 24:1827.
59. White FJ and Wang RY (1983a) Comparison of the effects of chronic haloperidol treatment on A9 and A10 dopamine neurons. Life Sci 32:983-993.
60. White FJ and Wang RY (1983b) Differential effects of classical and atypical antipsychotic drugs on A9 and A10 dopamine neurons. Science (Wash DC) 221:1054-1057.
61. Williams K, Dichter MA and Molinoff PB (1992) Up-regulation of N-methyl-D-aspartate receptors on cultured cortical neurons after exposure to antagonists. Mol Pharmacol 42:147-151.
62. Wuarin JP, Peacock WJ and Dubek FE (1992) Single-electrode voltage clamp analysis of the N-methyl-D-aspartate component of synaptic responses in neocortical slices from children with intractable epilepsy. J Neurophysiol 67:84-93.
63. Yang CR, Seamans JK and Gorelova N (1996) Electrophysiological and morphological properties of layers V-VI principal pyramidal cells in rat prefrontal cortex in vitro. J Neurosci 16:1904-1921.
64. Zheng F and Gallagher JP (1995) Pharmacologically distinct, pertussis toxinresistant inward currents evoked by metabotropic glutamate receptor (mGluR) agonists in dorsolateral septal nucleus (DLSN) neurons. J Neurosci 15:504-510.